csirt@kutim:~/threat-intel/cve/CVE-2026-39304

Katalog CVE

CVSS 7.5 · High EPSS 1,1%

Kerentanan Uncontrolled Resource Consumption pada apache activemq, apache activemq broker. Skor CVSS 3.1 7.5 (High) menurut CISA ADP.

Deskripsi (NVD)

Denial of Service via Out of Memory vulnerability in Apache ActiveMQ Client, Apache ActiveMQ Broker, Apache ActiveMQ. ActiveMQ NIO SSL transports do not correctly handle TLSv1.3 handshake KeyUpdates triggered by clients. This makes it possible for a client to rapidly trigger updates which causes the broker to exhaust all its memory in the SSL engine leading to DoS. Note: TLS versions before TLSv1.3 (such as TLSv1.2) are broken but are not vulnerable to OOM. Previous TLS versions require a full handshake renegotiation which causes a connection to hang but not OOM. This is fixed as well. This issue affects Apache ActiveMQ Client: before 5.19.4, from 6.0.0 before 6.2.4; Apache ActiveMQ Broker: before 5.19.4, from 6.0.0 before 6.2.4; Apache ActiveMQ: before 5.19.4, from 6.0.0 before 6.2.4. Users are recommended to upgrade to version 6.2.4 or 5.19.5, which fixes the issue.

Rincian

Terbit di NVD
10 April 2026
Terakhir diubah
15 Juli 2026
Status NVD
Modified
CVSS 3.1
7.5 (High), sumber CISA ADP
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-400: Uncontrolled Resource Consumption
CWE-770: Allocation of Resources Without Limits or Throttling
EPSS (30 hari)
1,1% peluang dieksploitasi; lebih tinggi dari 63,8% CVE lain

Produk dan versi terdampak

VendorProdukVersi terdampak
apache activemq Semua versi sebelum 5.19.4
apache activemq Versi 6.0.0 hingga sebelum 6.2.4
apache activemq broker Semua versi sebelum 5.19.4
apache activemq broker Versi 6.0.0 hingga sebelum 6.2.4

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.